Timing map / evidence context
A cautious, non-promotional outline of how ibogaine effects and risks may unfold—from onset through the longer pharmacologic and cardiac window.
How to read this page
Ibogaine is a psychoactive indole alkaloid associated with complex and prolonged effects, but published observations do not establish one reliable hour-by-hour experience for every person. This page uses broad windows to organize reported effects and pharmacologic context—not to predict an individual outcome.
For a wider overview of the subject, the Ebon Phase introduction to ibogaine timing and risk places this timeline alongside the uncertainty that surrounds the available evidence. Variation can be substantial with dose, route, CYP2D6 metabolism, co-medications, concurrent medical conditions, and opioid withdrawal. CYP2D6 matters because it contributes to conversion of ibogaine to noribogaine; a National Library of Medicine pharmacogenetics reference describes how CYP2D6 variation can affect drug metabolism more broadly.
Hours are useful for orientation, but they cannot establish safety, suitability, or a medical plan.
Experience windows
Reports may include nausea, dizziness, tremor, changes in coordination, anxiety, and an emerging alteration in perception. Physiological observations can include changes in heart rate or blood pressure, while vomiting may occur. The timing and intensity of these effects are not fixed, especially when withdrawal, other substances, or medicines are involved.
This window is often described as a period of pronounced perceptual, cognitive, and emotional effects, with reduced ability to move around safely. Nausea and vomiting can continue. The presence of subjective effects does not show whether cardiac electrical effects are absent; those are separate clinical concerns.
Some accounts describe an extended introspective or dreamlike period, exhaustion, and difficulty sleeping even as the most intense effects change. Published case reports and reviews describe serious adverse outcomes in this broader period as well as earlier, which is why duration should never be treated as a safety boundary.
Fatigue, residual perceptual changes, nausea, low appetite, emotional sensitivity, and disrupted sleep may be reported. People can still be impaired. The transition away from the acute experience does not necessarily match clearance of ibogaine or its metabolite from the body.
Persistence and uncertainty
Over the next one to three days, some people describe tiredness, poor sleep, lingering nausea, low mood, heightened emotion, or a gradual return of ordinary appetite and routine. Others report a longer adjustment period. These descriptions are not proof of benefit, and they do not rule out delayed or continuing medical concern.
Noribogaine, an active metabolite, can persist beyond the acute subjective experience. Its timing depends in part on metabolic differences, including CYP2D6 activity, and may be altered by co-medications. That persistence is one reason it is misleading to assume that feeling less altered means all pharmacologic effects have ended.
From roughly three days to two weeks, recovery descriptions remain highly variable. Sleep, mood, energy, bowel function, and opioid withdrawal can each shift the perceived timeline. A broader aftercare and recovery timeline can help distinguish these later adjustments from the acute window, without turning either into a promise of what will happen.
Exposure can differ with the amount and route involved; reports should not be generalized across unlike circumstances.
CYP2D6 variation can change how quickly ibogaine is converted to noribogaine and how long compounds may persist.
Other substances and medications can change risk, including cardiac risk, seizure risk, and withdrawal complexity.
“Typical” does not mean safe. A timeline cannot identify who may experience a serious complication.
Evidence limits
Study designs, formulations, observation periods, participant health, withdrawal state, and concurrent drug exposure differ. Case series can identify patterns and harms, but they cannot reliably forecast one person’s response.
Ibogaine has been associated with QT prolongation and arrhythmia in published reports. QT interval change is clinically important because it can be associated with dangerous rhythm disturbances, as summarized by the American Heart Association’s explanation of long QT syndrome.
It can. Withdrawal symptoms, dehydration, stress, sleep loss, and other substances can complicate both subjective reporting and medical risk. A focused discussion of ibogaine and opioid treatment claims should be read cautiously and never as a substitute for individualized medical care.
At every stage. The available literature includes reviews, observational work, pharmacokinetic research, and adverse-event reports, but does not justify a universal timetable or an assumption of safety. Ebon Phase’s approach to evidence and uncertainty explains why clear limits matter in this topic area.
Keep the risk context in view
Questions about products, settings, and treatment marketing can obscure the basic issue: ibogaine can involve unpredictable and serious medical risks. Information about ibogaine market exposure, California treatment claims, Bwiti-related ibogaine context, comparisons of treatment centers, and Mexico facility information should not be mistaken for clinical clearance or personal medical guidance. For the cardiac dimension specifically, see the safety and cardiac risk overview.